Liver/Biliary Disorders News

Vibration-controlled transient elastography-based Agile scores accurately predicted liver-related events in patients with metabolic dysfunction-associated steatotic liver disease and “may be suitable alternatives” to routine liver biopsy.

In this video, Sarah L. Maxwell, MD, and Janet M. Wojcicki, PhD, MPH, discuss a reported link between food insecurity at age 4 years and an increased risk for metabolic dysfunction-associated steatotic liver disease among Latino children.

Daily low-dose aspirin “significantly reduced” hepatic fat quantity at 6 months compared with placebo among patients with metabolic dysfunction-associated steatotic liver disease, according to preliminary trial results published in JAMA.

While the CDC estimated that excessive alcohol use contributed to approximately 178,000 U.S. deaths each year from 2020 to 2021, an emerging lifestyle trend may help counter those statistics in the years ahead.

The FDA has updated the label indication for Vemlidy 25 mg for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 6 years and older who weigh at least 25 kg.

Efruxifermin with a glucagon-like peptide-1 receptor agonist was well-tolerated and reduced hepatic fat fraction and noninvasive markers of fibrosis among patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes.

The average number of deaths from excessive alcohol use increased by 29.3% from 2016 to 2021, with an age-standardized rise in death rate from 38.1 to 47.6 per 100,000 population, according to data in Morbidity and Mortality Weekly Report.

A “significantly greater” percentage of patients with primary biliary cholangitis achieved biochemical response, alkaline phosphatase normalization and reduction in pruritis when treated with seladelpar vs. placebo, according to a study.

Madrigal Pharmaceutical’s Rezdiffra received accelerated FDA approval for the treatment of patients with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, according to a company release.

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.